Overview

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Status:
Terminated

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Lenalidomide may stop the growth of cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with doxorubicin hydrochloride liposome may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of lenalidomide when given together with doxorubicin hydrochloride liposome in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Masonic Cancer Center, University of Minnesota

Collaborator:

Celgene Corporation

Treatments:

Doxorubicin
Lenalidomide
Liposomal doxorubicin
Thalidomide